Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 16/20 | 0.35 |
| ▸ | CNR1 | P21554 | 14/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557854 | 0.92 | ITGB3 (0.36) | KMT2A | |
| SCHEMBL557969 | 0.92 | ITGB3 (0.36) | KMT2A | |
| SCHEMBL10099812 | 0.92 | ITGB3 (0.36) | KMT2A | |
| SCHEMBL2926216 | 0.86 | PLA2G2A (0.35) | KMT2ACNR2CNR1 | |
| SCHEMBL4087824 | 0.85 | ITGB3 (0.38) | — | |
| SCHEMBL24819248 | 0.84 | KMT2A (0.44) | KMT2APOLB | |
| SCHEMBL1887808 | 0.84 | KMT2A (0.44) | KMT2APOLB | |
| SCHEMBL20467657 | 0.84 | KMT2A (0.44) | KMT2APOLB | |
| SCHEMBL20450544 | 0.84 | KMT2A (0.44) | KMT2APOLB | |
| SCHEMBL20144613 | 0.84 | KMT2A (0.44) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722620-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| EP-2256129-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1991576-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2010-09-29 | — | — | EP | disclosed |
| US-20090137454-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137454-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | KMT2A 3453/4885CNR2 4031/4885CNR1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.